Search

Your search keyword '"Niven Mehra"' showing total 225 results

Search Constraints

Start Over You searched for: Author "Niven Mehra" Remove constraint Author: "Niven Mehra"
225 results on '"Niven Mehra"'

Search Results

201. Myeloid-derived suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients (PTS)

202. Abstract 4976: Monitoring CHD1 during prostate cancer progression

203. Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC)

204. Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS)

205. High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC)

206. Interrogating metastatic prostate cancer treatment switch decisions

207. Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis

208. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models

209. Identification of two new serum protein profiles for renal cell carcinoma

210. Identification of two new serum protein profiles for renal cell carcinoma

211. 2558 Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients

212. 2578 Neutrophil-to-lymphocyte ratio (NLR) in relation to outcome of castration-resistant prostate cancer (CRPC) patients treated with corticosteroids (CS)

213. 2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC)

214. Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results

215. The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery

216. Sequencing of Docetaxel (D) and Abiraterone Acetate (Aa) for Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

217. P13 Elevated, cell-free mitochondrial RNA in plasma identifies a poorprognosis in prostate, head and neck, kidney and colorectal cancerpatients

218. Use of serum proteins identified by proteomics to predict prognosis in patients with metastatic renal cell cancer (mRCC) and comparison to the currently used MSKCC survival model

219. P12 SELDI-TOF MS serum protein profiling predicts poor prognosis renal cancer patients

220. Endothelial progenitor marker CD133 mRNA expression in peripheral blood mononuclear cells predicts outcome of cancer patients

221. PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

222. Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel

223. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

224. PSA levels after dexamethasone withdrawal (DW) in castration resistant prostate cancer (CRPC)

225. MOESM8 of Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Catalog

Books, media, physical & digital resources